Could a higher dose of TB drug save kids with HIV?

NCT ID NCT05069688

Recruiting now Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study looks at whether a higher dose of the TB medicine rifampicin is safe and works well in children with both HIV and TB. Twenty children will take their usual HIV and TB drugs, but for two weeks the rifampicin dose will be increased. Researchers will measure drug levels in the blood to see if the higher dose improves treatment without causing harm.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rifampicin and dolutegravir
What this could lead to: If successful, this could lead to safer and more effective TB treatment for children with HIV, potentially shortening therapy duration.
What could go wrong: This is a very small early-phase study with only 20 children, so results may not apply broadly. High-dose rifampicin could also cause side effects or drug interactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEDIATRIC HIV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease latent tuberculosis infection tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PEDIATRIC HIV INFECTION TUBERCULOSIS INFECTION

Contacts and locations

Locations

University College Hospital/ University of Ibadan
RECRUITING

Ibadan, Oyo State, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.